Hal Barron, Hans Bishop
Grail has appointed Hal Barron and Hans Bishop to its board. Barron is the CSO and president of R&D at GlaxoSmithKline. Prior to that, he served as president of R&D at Calico. He has also held management positions at Roche Pharmaceuticals and Genentech and is associate adjunct professor of epidemiology and biostatistics at the University of California, San Francisco.
Bishop founded Juno Therapeutics in 2013 and was the firm's president and CEO until this past March when it was acquired by Celgene. He previously served as executive-in-residence at Warburg Pincus and is currently on the boards of Agilent Technologies and Celgene.
Mitchell Nelles
CareDx Chief Operating Officer Mitchell Nelles told the company on July 31 that he intends to retire, effective Sept. 28, according to a document filed with the US Securities Exchange Commission. Nelles joined CareDx in 2007, when it was called XDx, as VP of R&D. Prior to that, Nelles served as VP of North American R&D at BioMérieux.
Albert Parker
OncoCyte has appointed Albert Parker as its chief operating officer. According to the company, Parker is an attorney and executive with more than 25 years of pharmaceutical, biotech, and healthcare experience. Prior to joining OncoCyte, Parker served as the managing shareholder of GC Legal Advisors, where he represented and advised public and privately held companies, primarily in the life sciences industry. Among other prior roles, Parker has also served as executive VP, general counsel, and corporate secretary at Sunovion Pharmaceuticals, senior VP and chief counsel for Wyeth Pharmaceuticals, and partner at Schnader Harrison Segal & Lewis.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.